IceCure Medical is a medical device company innovating cryotherapy solutions to treat benign & malignant tumors with our liquid nitrogen based ProSense™ Cryoablation System for women’s health and interventional oncology. #freezecancernotyourlife
Founded in 2006 to advance the treatment of cancerous tumors, our FDA-cleared and CE-marked ProSense™ Cryoablation System utilizes liquid nitrogen to generate ultra-cold temperatures quickly to create large lethal zones for maximum efficacy in tumor destruction. The system achieves a sharp temperature decrease at the start of the freeze step and provides consistently stable freezing temperatures throughout the procedure. ProSense is a proven solution for the treatment of benign and malignant breast tumors, renal, lung, liver, and bone cancers.
The ProSense™ system is available in the US, Europe, across Asia in Singapore, Thailand, Japan, India, Taiwan, and South Africa. As of June 2022, the company entered into an exclusive distribution agreement with Shanghai Medtronic for Mainland China. In 2021, ProSense™ was granted FDA Breakthrough Device Designation for treatment of patients with T1 invasive breast cancer and/or patients not suitable for surgical alternatives for the treatment of breast cancer. IceCure is conducting the ICE3 Clinical Trial, the largest multi-center trial for cryoablation of small, low-risk breast cancer. Interim analysis of the ICE3 trial presented during ASBrS 2021 Annual Meeting show promising results - at a mean of 34.83 months following treatment with ProSense, only 2.06% (4 out of 194 eligible trial patients experience cancer recurrence.
IceCure’s team leaders are seasoned medical device and technology entrepreneurs, who have teamed up with world-renowned academics, clinical centers, and practitioners to establish advanced cryotherapy as the standard in oncology clinics worldwide.
